Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

Therapeutic advantages provided by banked virus-specific T-cells of defined HLA-restriction.

O'Reilly RJ, Prockop S, Hasan A, Doubrovina E.

Bone Marrow Transplant. 2019 Aug;54(Suppl 2):759-764. doi: 10.1038/s41409-019-0614-1. Review.

PMID:
31431697
2.

Adoptive immunotherapy with haploidentical natural killer cells and Anti-GD2 monoclonal antibody m3F8 for resistant neuroblastoma: Results of a phase I study.

Modak S, Le Luduec JB, Cheung IY, Goldman DA, Ostrovnaya I, Doubrovina E, Basu E, Kushner BH, Kramer K, Roberts SS, O'Reilly RJ, Cheung NV, Hsu KC.

Oncoimmunology. 2018 May 10;7(8):e1461305. doi: 10.1080/2162402X.2018.1461305. eCollection 2018.

3.

PARP Inhibitors in Clinical Use Induce Genomic Instability in Normal Human Cells.

Ito S, Murphy CG, Doubrovina E, Jasin M, Moynahan ME.

PLoS One. 2016 Jul 18;11(7):e0159341. doi: 10.1371/journal.pone.0159341. eCollection 2016.

4.

Virus-specific T-cell banks for 'off the shelf' adoptive therapy of refractory infections.

O'Reilly RJ, Prockop S, Hasan AN, Koehne G, Doubrovina E.

Bone Marrow Transplant. 2016 Sep;51(9):1163-72. doi: 10.1038/bmt.2016.17. Epub 2016 Apr 4. Review.

5.

Characterization of a c-Rel Inhibitor That Mediates Anticancer Properties in Hematologic Malignancies by Blocking NF-κB-Controlled Oxidative Stress Responses.

Shono Y, Tuckett AZ, Liou HC, Doubrovina E, Derenzini E, Ouk S, Tsai JJ, Smith OM, Levy ER, Kreines FM, Ziegler CG, Scallion MI, Doubrovin M, Heller G, Younes A, O'Reilly RJ, van den Brink MR, Zakrzewski JL.

Cancer Res. 2016 Jan 15;76(2):377-89. doi: 10.1158/0008-5472.CAN-14-2814. Epub 2016 Jan 7.

6.

Therapeutic bispecific T-cell engager antibody targeting the intracellular oncoprotein WT1.

Dao T, Pankov D, Scott A, Korontsvit T, Zakhaleva V, Xu Y, Xiang J, Yan S, de Morais Guerreiro MD, Veomett N, Dubrovsky L, Curcio M, Doubrovina E, Ponomarev V, Liu C, O'Reilly RJ, Scheinberg DA.

Nat Biotechnol. 2015 Oct;33(10):1079-86. doi: 10.1038/nbt.3349. Epub 2015 Sep 21.

7.

T-cell depleted allogeneic hematopoietic cell transplants as a platform for adoptive therapy with leukemia selective or virus-specific T-cells.

O'Reilly RJ, Koehne G, Hasan AN, Doubrovina E, Prockop S.

Bone Marrow Transplant. 2015 Jun;50 Suppl 2:S43-50. doi: 10.1038/bmt.2015.95. Review.

8.

Immunotherapy with Donor T Cells Sensitized with Overlapping Pentadecapeptides for Treatment of Persistent Cytomegalovirus Infection or Viremia.

Koehne G, Hasan A, Doubrovina E, Prockop S, Tyler E, Wasilewski G, O'Reilly RJ.

Biol Blood Marrow Transplant. 2015 Sep;21(9):1663-78. doi: 10.1016/j.bbmt.2015.05.015. Epub 2015 May 29.

9.

Treatment of cytomegalovirus retinitis with cytomegalovirus-specific T-lymphocyte infusion.

Gupta MP, Coombs P, Prockop SE, Hasan AA, Doubrovina E, O'Reilly RJ, Cohen SH, Park SS, Kiss S.

Ophthalmic Surg Lasers Imaging Retina. 2015 Jan;46(1):80-2. doi: 10.3928/23258160-20150101-14.

10.

A small-molecule c-Rel inhibitor reduces alloactivation of T cells without compromising antitumor activity.

Shono Y, Tuckett AZ, Ouk S, Liou HC, Altan-Bonnet G, Tsai JJ, Oyler JE, Smith OM, West ML, Singer NV, Doubrovina E, Pankov D, Undhad CV, Murphy GF, Lezcano C, Liu C, O'Reilly RJ, van den Brink MR, Zakrzewski JL.

Cancer Discov. 2014 May;4(5):578-91. doi: 10.1158/2159-8290.CD-13-0585. Epub 2014 Feb 18.

11.

Targeting the intracellular WT1 oncogene product with a therapeutic human antibody.

Dao T, Yan S, Veomett N, Pankov D, Zhou L, Korontsvit T, Scott A, Whitten J, Maslak P, Casey E, Tan T, Liu H, Zakhaleva V, Curcio M, Doubrovina E, O'Reilly RJ, Liu C, Scheinberg DA.

Sci Transl Med. 2013 Mar 13;5(176):176ra33. doi: 10.1126/scitranslmed.3005661.

12.

Mapping of novel peptides of WT-1 and presenting HLA alleles that induce epitope-specific HLA-restricted T cells with cytotoxic activity against WT-1(+) leukemias.

Doubrovina E, Carpenter T, Pankov D, Selvakumar A, Hasan A, O'Reilly RJ.

Blood. 2012 Aug 23;120(8):1633-46. doi: 10.1182/blood-2011-11-394619. Epub 2012 May 23.

13.

Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation.

Doubrovina E, Oflaz-Sozmen B, Prockop SE, Kernan NA, Abramson S, Teruya-Feldstein J, Hedvat C, Chou JF, Heller G, Barker JN, Boulad F, Castro-Malaspina H, George D, Jakubowski A, Koehne G, Papadopoulos EB, Scaradavou A, Small TN, Khalaf R, Young JW, O'Reilly RJ.

Blood. 2012 Mar 15;119(11):2644-56. doi: 10.1182/blood-2011-08-371971. Epub 2011 Dec 2.

14.

Novel strategies for adoptive therapy following HLA disparate transplants.

O'Reilly RJ, Hasan A, Doubrovina E, Koehne G, Prockop S.

Best Pract Res Clin Haematol. 2011 Sep;24(3):381-91. doi: 10.1016/j.beha.2011.06.001. Review.

15.

Successful treatment of EBV-associated posttransplantation lymphoma after cord blood transplantation using third-party EBV-specific cytotoxic T lymphocytes.

Barker JN, Doubrovina E, Sauter C, Jaroscak JJ, Perales MA, Doubrovin M, Prockop SE, Koehne G, O'Reilly RJ.

Blood. 2010 Dec 2;116(23):5045-9. doi: 10.1182/blood-2010-04-281873. Epub 2010 Sep 8.

16.

Adoptive transfer of unselected or leukemia-reactive T-cells in the treatment of relapse following allogeneic hematopoietic cell transplantation.

O'Reilly RJ, Dao T, Koehne G, Scheinberg D, Doubrovina E.

Semin Immunol. 2010 Jun;22(3):162-72. doi: 10.1016/j.smim.2010.02.003. Epub 2010 May 26. Review.

17.

Artificial antigen presenting cells that express prevalent HLA alleles: A step towards the broad application of antigen-specific adoptive cell therapies.

Hasan AN, Selvakumar A, Doubrovina E, Riviere I, Sadelain MW, O'Reilly RJ.

Discov Med. 2009 Dec;8(43):210-8. Review.

18.

In vivo imaging and quantitation of adoptively transferred human antigen-specific T cells transduced to express a human norepinephrine transporter gene.

Doubrovin MM, Doubrovina ES, Zanzonico P, Sadelain M, Larson SM, O'Reilly RJ.

Cancer Res. 2007 Dec 15;67(24):11959-69.

19.

Adoptive transfer of antigen-specific T-cells of donor type for immunotherapy of viral infections following allogeneic hematopoietic cell transplants.

O'Reilly RJ, Doubrovina E, Trivedi D, Hasan A, Kollen W, Koehne G.

Immunol Res. 2007;38(1-3):237-50.

PMID:
17917029
20.

[131I]FIAU labeling of genetically transduced, tumor-reactive lymphocytes: cell-level dosimetry and dose-dependent toxicity.

Zanzonico P, Koehne G, Gallardo HF, Doubrovin M, Doubrovina E, Finn R, Blasberg RG, Riviere I, O'Reilly RJ, Sadelain M, Larson SM.

Eur J Nucl Med Mol Imaging. 2006 Sep;33(9):988-97. Epub 2006 Apr 11.

PMID:
16607546
21.
22.

Targeted deletion of T-cell clones using alpha-emitting suicide MHC tetramers.

Yuan RR, Wong P, McDevitt MR, Doubrovina E, Leiner I, Bornmann W, O'reilly R, Pamer EG, Scheinberg DA.

Blood. 2004 Oct 15;104(8):2397-402. Epub 2004 Jun 24.

PMID:
15217835
23.

Evasion from NK cell immunity by MHC class I chain-related molecules expressing colon adenocarcinoma.

Doubrovina ES, Doubrovin MM, Vider E, Sisson RB, O'Reilly RJ, Dupont B, Vyas YM.

J Immunol. 2003 Dec 15;171(12):6891-9.

24.

Insulin-like growth factor-I enhances lymphoid and myeloid reconstitution after allogeneic bone marrow transplantation.

Alpdogan O, Muriglan SJ, Kappel BJ, Doubrovina E, Schmaltz C, Schiro R, Eng JM, Greenberg AS, Willis LM, Rotolo JA, O'Reilly RJ, van den Brink MR.

Transplantation. 2003 Jun 27;75(12):1977-83.

PMID:
12829897
25.

Serial in vivo imaging of the targeted migration of human HSV-TK-transduced antigen-specific lymphocytes.

Koehne G, Doubrovin M, Doubrovina E, Zanzonico P, Gallardo HF, Ivanova A, Balatoni J, Teruya-Feldstein J, Heller G, May C, Ponomarev V, Ruan S, Finn R, Blasberg RG, Bornmann W, Riviere I, Sadelain M, O'Reilly RJ, Larson SM, Tjuvajev JG.

Nat Biotechnol. 2003 Apr;21(4):405-13. Epub 2003 Mar 24.

PMID:
12652311

Supplemental Content

Loading ...
Support Center